Literature DB >> 27872063

In Vitro Exposure to Increasing Micafungin Concentrations Easily Promotes Echinocandin Resistance in Candida glabrata Isolates.

María Ángeles Bordallo-Cardona1,2, Pilar Escribano3,2, Elia Gómez G de la Pedrosa4,5, Laura Judith Marcos-Zambrano1,2, Rafael Cantón4,5, Emilio Bouza1,2,6,7, Jesús Guinea3,2,6,7.   

Abstract

We assessed the in vitro susceptibility of five echinocandin-susceptible Candida glabrata isolates after exposure to micafungin. The direct exposure to plates at different micafungin concentrations resulted in the inhibition of growth at 0.062 μg/ml. The progressive exposure was performed on plates using 0.031 μg/ml of micafungin and sequential propagation on plates containing the next 2-fold concentration; the MICs of micafungin and anidulafungin increased sequentially, and all the isolates became echinocandin resistant, showing fks2 mutations.
Copyright © 2017 American Society for Microbiology.

Entities:  

Keywords:  Candida glabrata; FKS; echinocandin; fks mutation; micafungin

Mesh:

Substances:

Year:  2017        PMID: 27872063      PMCID: PMC5278751          DOI: 10.1128/AAC.01542-16

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  14 in total

1.  In vitro acquisition of secondary azole resistance in Aspergillus fumigatus isolates after prolonged exposure to itraconazole: presence of heteroresistant populations.

Authors:  Pilar Escribano; Sandra Recio; Teresa Peláez; Milagros González-Rivera; Emilio Bouza; Jesús Guinea
Journal:  Antimicrob Agents Chemother       Date:  2011-10-17       Impact factor: 5.191

2.  EUCAST technical note on the EUCAST definitive document EDef 7.2: method for the determination of broth dilution minimum inhibitory concentrations of antifungal agents for yeasts EDef 7.2 (EUCAST-AFST).

Authors:  Maiken C Arendrup; Manuel Cuenca-Estrella; Cornelia Lass-Flörl; William Hope
Journal:  Clin Microbiol Infect       Date:  2012-05-08       Impact factor: 8.067

3.  ESCMID* guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients.

Authors:  O A Cornely; M Bassetti; T Calandra; J Garbino; B J Kullberg; O Lortholary; W Meersseman; M Akova; M C Arendrup; S Arikan-Akdagli; J Bille; E Castagnola; M Cuenca-Estrella; J P Donnelly; A H Groll; R Herbrecht; W W Hope; H E Jensen; C Lass-Flörl; G Petrikkos; M D Richardson; E Roilides; P E Verweij; C Viscoli; A J Ullmann
Journal:  Clin Microbiol Infect       Date:  2012-12       Impact factor: 8.067

4.  FKS mutations and elevated echinocandin MIC values among Candida glabrata isolates from U.S. population-based surveillance.

Authors:  Alicia J Zimbeck; Naureen Iqbal; Angela M Ahlquist; Monica M Farley; Lee H Harrison; Tom Chiller; Shawn R Lockhart
Journal:  Antimicrob Agents Chemother       Date:  2010-09-13       Impact factor: 5.191

5.  Development of caspofungin resistance following prolonged therapy for invasive candidiasis secondary to Candida glabrata infection.

Authors:  George R Thompson; Nathan P Wiederhold; Ana C Vallor; Nyria C Villareal; James S Lewis; Thomas F Patterson
Journal:  Antimicrob Agents Chemother       Date:  2008-08-01       Impact factor: 5.191

6.  Increasing echinocandin resistance in Candida glabrata: clinical failure correlates with presence of FKS mutations and elevated minimum inhibitory concentrations.

Authors:  Barbara D Alexander; Melissa D Johnson; Christopher D Pfeiffer; Cristina Jiménez-Ortigosa; Jelena Catania; Rachel Booker; Mariana Castanheira; Shawn A Messer; David S Perlin; Michael A Pfaller
Journal:  Clin Infect Dis       Date:  2013-03-13       Impact factor: 9.079

7.  Molecular identification and antifungal susceptibility of yeast isolates causing fungemia collected in a population-based study in Spain in 2010 and 2011.

Authors:  Jesús Guinea; Óscar Zaragoza; Pilar Escribano; Estrella Martín-Mazuelos; Javier Pemán; Ferrán Sánchez-Reus; Manuel Cuenca-Estrella
Journal:  Antimicrob Agents Chemother       Date:  2013-12-23       Impact factor: 5.191

8.  Abdominal candidiasis is a hidden reservoir of echinocandin resistance.

Authors:  Ryan K Shields; M Hong Nguyen; Ellen G Press; Cornelius J Clancy
Journal:  Antimicrob Agents Chemother       Date:  2014-10-06       Impact factor: 5.191

9.  Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America.

Authors:  Peter G Pappas; Carol A Kauffman; David R Andes; Cornelius J Clancy; Kieren A Marr; Luis Ostrosky-Zeichner; Annette C Reboli; Mindy G Schuster; Jose A Vazquez; Thomas J Walsh; Theoklis E Zaoutis; Jack D Sobel
Journal:  Clin Infect Dis       Date:  2015-12-16       Impact factor: 9.079

Review 10.  Echinocandin resistance: an emerging clinical problem?

Authors:  Maiken C Arendrup; David S Perlin
Journal:  Curr Opin Infect Dis       Date:  2014-12       Impact factor: 4.915

View more
  9 in total

1.  Mutant Prevention Concentration and Mutant Selection Window of Micafungin and Anidulafungin in Clinical Candida glabrata Isolates.

Authors:  Pilar Escribano; Jesús Guinea; María Ángeles Bordallo-Cardona; Laura Judith Marcos-Zambrano; Carlos Sánchez-Carrillo; Elia Gómez G de la Pedrosa; Rafael Cantón; Emilio Bouza
Journal:  Antimicrob Agents Chemother       Date:  2018-02-23       Impact factor: 5.191

2.  MSH2 Gene Point Mutations Are Not Antifungal Resistance Markers in Candida glabrata.

Authors:  Pilar Escribano; Jesús Guinea; María Ángeles Bordallo-Cardona; Caroline Agnelli; Ana Gómez-Nuñez; Carlos Sánchez-Carrillo; Emilio Bouza; Patricia Muñoz
Journal:  Antimicrob Agents Chemother       Date:  2018-12-21       Impact factor: 5.191

3.  Anidulafungin Susceptibility Testing of Candida glabrata Isolates from Blood Cultures by the MALDI Biotyper Antibiotic (Antifungal) Susceptibility Test Rapid Assay.

Authors:  Mansoureh Vatanshenassan; Amir Arastehfar; Teun Boekhout; Judith Berman; Cornelia Lass-Flörl; Katrin Sparbier; Markus Kostrzewa
Journal:  Antimicrob Agents Chemother       Date:  2019-08-23       Impact factor: 5.191

4.  Risk Factors and Clinical Characteristics of Patients with Ocular Candidiasis.

Authors:  Toru Sakamoto; Kenji Gotoh; Kenyu Hashimoto; Chiyoko Tanamachi; Hiroshi Watanabe
Journal:  J Fungi (Basel)       Date:  2022-05-11

5.  Update from a 12-Year Nationwide Fungemia Surveillance: Increasing Intrinsic and Acquired Resistance Causes Concern.

Authors:  K M T Astvad; H K Johansen; B L Røder; F S Rosenvinge; J D Knudsen; L Lemming; H C Schønheyder; R K Hare; L Kristensen; L Nielsen; J B Gertsen; E Dzajic; M Pedersen; C Østergård; B Olesen; T S Søndergaard; M C Arendrup
Journal:  J Clin Microbiol       Date:  2018-03-26       Impact factor: 5.948

6.  Resistance to Echinocandins in Candida Can Be Detected by Performing the Etest Directly on Blood Culture Samples.

Authors:  Pilar Escribano; Jesús Guinea; María Ángeles Bordallo-Cardona; Laura Judith Marcos-Zambrano; Carlos Sánchez-Carrillo; Emilio Bouza; Patricia Muñoz
Journal:  Antimicrob Agents Chemother       Date:  2018-05-25       Impact factor: 5.191

7.  Notable Increasing Trend in Azole Non-susceptible Candida tropicalis Causing Invasive Candidiasis in China (August 2009 to July 2014): Molecular Epidemiology and Clinical Azole Consumption.

Authors:  Xin Fan; Meng Xiao; Kang Liao; Timothy Kudinha; He Wang; Li Zhang; Xin Hou; Fanrong Kong; Ying-Chun Xu
Journal:  Front Microbiol       Date:  2017-03-22       Impact factor: 5.640

8.  A Noncanonical DNA Damage Checkpoint Response in a Major Fungal Pathogen.

Authors:  Erika Shor; Rocio Garcia-Rubio; Lucius DeGregorio; David S Perlin
Journal:  mBio       Date:  2020-12-15       Impact factor: 7.867

9.  Azole-resistant Aspergillus and Echinocandin-resistant Candida - What are the treatment options?

Authors:  Alison R Novak; Mary E Bradley; Tyree H Kiser; Scott W Mueller
Journal:  Curr Fungal Infect Rep       Date:  2020-03-26
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.